Table 1. Demographics and medical characteristics of participants.

Participants (n = 104)	Group 1 50-60 (Q1) n = 36	Group 2 61-69 (Q2) n = 35	Group 3 70-87 (Q3) n = 33	P-value
Data are presented as mean ± SD or n (%). BMI: body mass index; BP: blood pressure.
Female	13 (36.1%)	16 (45.7%)	14 (42.4%)	0.705
Male	23 (63.9%)	19 (54.3%)	19 (57.6%)
Race
White	30 (83.3%)	30 (85.7%)	31 (93.9%)	0.505
Non-white	5 (13.9%)	3 (8.6%)	1 (3.1%)
Unknown	1 (2.8%)	2 (5.7%)	1 (3.0%)
Past medical history​
Congestive heart failure​	1 (2.8%)	3 (2.9%)	3 (2.9%)	0.502
Cardiac arrhythmias​	3 (8.3%)	5 (14.3%)	7 (21.2%)	0.314
Valvular disease​	4 (11.1%)	2 (5.7%)	5 (15.2%)	0.446
Vascular disease​	10 (27.8%)	5 (14.3%)	13 (39.4%)	0.065
Hypertension​	25 (69.4%)	26 (74.3%)	28 (84.9%)	0.314
Diabetes​	8 (22.2%)	7 (20.0%)	11 (33.3%)	0.399
Hyperlipidemia​	31 (86.1%)	33 (94.3%)	26 (78.8%)	0.173
Chronic pulmonary disease​	2 (5.6%)	6 (17.1%)	2 (6.1%)	0.179
Renal disease​	2 (5.6%)	1 (2.9%)	2 (6.1%)	0.799
Major bleeding event or predisposition to bleeding​	1 (2.8%)	4 (11.4%)	2 (6.1%)	0.341
Prior myocardial infarction​	7 (19.4%)	2 (5.7%)	10 (30.3%)	0.031*
Sleep apnea​	5 (13.9%)	13 (37.1%)	10 (30.3%)	0.076
Treatment history​
Percutaneous coronary intervention​	3 (8.3%)	1 (2.9%)	8 (24.2%)	0.017*
Cardiac surgery​	2 (5.6%)	4 (11.4%)	8 (24.2%)	0.069
Anti-arrhythmic medication​	0 (0%)	2 (5.7%)	0 (0%)	0.134
Beta blocker​	15 (41.7%)	12 (34.3%)	20 (60.6%)	0.081
Calcium channel blocker​	5 (13.9%)	8 (22.9%)	8 (24.2%)	0.502
Hypertension medication​	19 (52.8%)	17 (48.6%)	24 (72.7%)	0.100
Antiplatelet medication​	30 (83.3%)	31 (88.6%)	29 (87.9%)	0.782
Anticoagulant​	5 (13.9%)	4 (11.4%)	4 (12.1%)	0.949
Statin use​	32 (88.9%)	33 (94.3%)	30 (90.9%)	0.717
Vitals​
BMI	28.1 ± 5.1	30.9 ± 12.3	36.1 ± 32.2	0.237
Diastolic BP	78.7 ±7.7	76.7 ± 9.7	72.3 ± 8.2	0.011*
Systolic BP	129.0 ± 16.9	130.6 ± 14.3	132.8 ± 18.7	0.643
Heart rate	78.0 ± 15.6	73.9 ± 13.1	68.3 ± 12.0	0.017*